Trial Profile
A real-life, pilot study to evaluate the efficacy and safety of sofosbuvir plus simeprevir combination without ribavirin for the re-treatment of patients with chronic hepatitis C virus genotype 1 or 4 infection and who previously failed a daclatasvir-containing regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2016
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- 12 Feb 2016 New trial record
- 08 Feb 2016 Results published in the Hepatology.